Long-term complete remission following tandem autologous stem cell transplantation and consolidative radiotherapy for refractory mediastinal gray-zone lymphoma

Mediastinal gray zone lymphoma (MGZL) is a provisional entity with intermediate features between classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma. Outcomes for patients with MGZL are reportedly poorer than those for patients with cHL or primary mediastinal large B-cell lymphoma. Ad...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2018-10, Vol.108 (4), p.452-455
Main Authors: Takaishi, Koji, Muto, Tomoya, Mimura, Naoya, Takiguchi, Jun, Nagao, Yuhei, Oshima-Hasegawa, Nagisa, Tsukamoto, Shokichi, Takeda, Yusuke, Mitsukawa, Shio, Takeuchi, Masahiro, Ohwada, Chikako, Ota, Satoshi, Iseki, Tohru, Nakaseko, Chiaki, Sakaida, Emiko
Format: Article
Language:English
Subjects:
Autografts
B-cell lymphoma
Case Report
Chemotherapy
Complications
Cyclophosphamide
Doxorubicin
Etoposide
Hematology
Hodgkin's lymphoma
Lymphocytes B
Lymphoma
Medicine
Medicine & Public Health
Monoclonal antibodies
Oncology
Patients
Prednisolone
Radiation therapy
Remission
Remission (Medicine)
Rituximab
Stem cell transplantation
Stem cells
Targeted cancer therapy
Transplantation
Vincristine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mediastinal gray zone lymphoma (MGZL) is a provisional entity with intermediate features between classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma. Outcomes for patients with MGZL are reportedly poorer than those for patients with cHL or primary mediastinal large B-cell lymphoma. Additionally, no standard management guidelines for patients with MGZL are available, primarily due to its recent identification, rarity, and challenges in diagnosis. Although recent several studies have suggested dose-adjusted EPOCH-R (etoposide, doxorubicin, vincristine, cyclophosphamide, prednisolone, and rituximab) may improve outcomes in patients with MGZL, numerous patients still suffer from relapsed/refractory MGZL, and the optimal management for such patients remains uncertain. Here, we report the first case of successful treatment of refractory MGZL by tandem high-dose chemotherapy supported by autologous stem cell transplantations (auto-SCTs) and consolidative radiotherapy (RT). To date, the patient remains in CR 33 months after the completion of RT, with no significant complications. This case suggests that tandem auto-SCTs may be a promising therapeutic option for relapsed/refractory MGZL.
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-018-2471-x